declar
dengu
pandem
sentinel
call
action
fight
rang
emerg
arbovir
diseas
human
past
year
seen
dramat
epidem
arbovir
diseas
recent
outbreak
neurolog
disord
neonat
malform
associ
zika
viru
zikv
infect
latin
america
yellow
fever
yfv
epidem
angola
brazil
import
china
everexpand
west
nile
viru
wnv
epidem
america
recent
emerg
east
africa
global
spread
chikungunya
viru
chikv
well
ongo
expand
dengu
viru
denv
pandem
tropic
subtrop
reinforc
call
action
fight
emerg
reemerg
arbovir
diseas
epidem
underscor
urgenc
need
integr
control
prevent
arbovir
diseas
especi
transmit
aed
mosquito
urban
area
prevent
control
strategi
current
focus
vector
control
includ
insecticid
treatment
environment
manag
social
mobil
effect
practic
wide
recogn
strategi
alon
fulli
address
problem
howev
intervent
tool
help
reduc
diseas
burden
exampl
time
access
clinic
servic
appropri
care
reduc
mortal
dramat
indoor
residu
spray
ir
indoor
space
spray
iss
may
effect
reduc
mosquito
popul
exposur
arbovirus
addit
person
protect
clinic
diagnosi
manag
laboratorybas
surveil
vaccin
effect
vaccin
avail
protect
japanes
enceph
yellow
fever
first
dengu
vaccin
even
though
limit
applic
licens
dr
duan
gubler
dukenu
medic
school
singapor
remind
audienc
frequenc
magnitud
arbovir
epidem
extent
geograph
spread
progress
increas
time
acceler
past
year
occur
global
tropic
http
illustr
denv
found
less
endem
countri
thousand
case
report
year
contrast
viru
becom
endem
countri
caus
estim
million
yearli
infect
million
symptomat
case
denv
serotyp
could
found
southeast
asia
earli
four
serotyp
denv
dramat
spread
region
tropic
similarli
new
strain
chikv
emerg
east
africa
spread
asia
rest
tropic
world
year
epidem
zikv
emerg
pacif
spread
around
world
year
virus
transmit
urban
mosquito
aed
aegypti
west
nile
viru
wnv
transmit
primarili
bird
feed
culex
mosquito
introduc
western
hemispher
first
time
rapidli
spread
east
coast
usa
rest
countri
canada
invad
caribbean
central
south
america
case
wnv
enceph
hors
case
human
report
usa
wnv
enzoot
region
dr
joao
bosco
siqueira
institut
tropic
patholog
public
health
goia
brazil
describ
anoth
dramat
exampl
yellow
fever
also
transmit
aed
aegypti
mosquito
wide
preval
tropic
includ
tropic
america
countri
subsaharan
africa
yellow
fever
emerg
expand
south
southeastern
part
brazil
yellow
fever
vaccin
common
emerg
central
brazil
infect
mani
travel
case
yellow
fever
export
brazil
europ
peru
usa
viru
continu
spread
area
bahia
rio
sao
paolo
detect
municip
caus
small
urban
epidem
death
toll
increas
person
first
half
africa
yellow
fever
spread
angola
democrat
republ
congo
emerg
nigeria
uganda
dramat
case
import
angola
china
first
time
histori
confirm
yellow
fever
introduc
asia
outlin
dr
duan
gubler
new
worrisom
aspect
emerg
arboviru
epidem
occur
urban
center
observ
dengu
fever
zika
chikungunya
yellow
fever
urban
vector
aed
mosquito
primarili
aed
aegypti
spread
around
world
past
centuri
secondarili
aed
albopictu
whose
spread
began
emerg
spread
dengu
chikungunya
zika
infect
actual
reflect
grow
geograph
spread
aed
spp
across
contin
fact
arbovir
diseas
becom
major
threat
urban
popul
result
popul
growth
urban
result
crowd
human
inadequ
hous
wast
manag
accumul
trash
includ
use
automobil
tire
plastic
tin
etc
creat
ideal
ecolog
condit
urban
aed
popul
thrive
spread
aed
spp
mosquito
around
world
throughout
tropic
subtrop
lack
effect
vector
control
infecti
diseas
prevent
global
air
transport
facilit
rapid
spread
pathogen
diseas
caus
billion
passeng
travel
air
line
year
trend
continu
epidem
arbovir
diseas
increasingli
threaten
global
nation
local
polit
econom
secur
could
creat
global
public
health
emerg
similar
even
greater
current
pandem
one
forget
billion
peopl
live
area
expos
urban
aed
mosquito
dr
duan
gubler
also
note
sinc
arbovir
diseas
repres
major
threat
urban
popul
necessari
reassess
surveil
strategi
current
surveil
system
base
passiv
report
loos
defin
clinic
syndrom
infrequ
laboratori
confirm
suggest
atrisk
countri
enhanc
passiv
diseas
surveil
system
base
welldefin
case
definit
support
serolog
virolog
laboratori
test
three
major
arboviru
patholog
monitor
system
febril
syndrom
haemorrhag
diseas
syndrom
meningoenceph
syndrom
activ
laboratorybas
syndrom
surveil
network
also
badli
need
weekli
report
local
physician
done
brazil
turn
use
also
encourag
howev
discuss
dr
elizabeth
hunsperg
cdc
atlanta
usa
differenti
diagnosi
clinic
set
may
difficult
especi
outsid
season
diseas
mild
asymptomat
infect
common
exampl
laboratori
test
dengu
import
order
distinguish
diseas
febril
ill
malaria
leptospirosi
influenza
arboviru
diseas
chikungunya
zika
west
nile
japanes
enceph
yellow
fever
even
typhoidparatyphoid
salmonella
typhi
salmonella
paratyphi
spp
bacteria
recent
recommend
serotest
individu
dengu
vaccin
set
screen
evid
past
infect
these
object
requir
differ
test
characterist
standard
dengu
diagnost
assay
includ
rtpcr
viru
neutral
assay
immunoassay
detect
denv
antigen
assay
detect
antidenv
igm
ref
sensit
specif
assay
rtpcr
elisa
assay
lowcost
pointofcar
poc
rapid
diagnost
test
rdt
current
adequ
clinic
vaccin
set
elisa
rtpcr
strategi
much
higher
level
perform
slow
costli
latter
test
need
public
health
surveil
research
set
diagnost
approach
instrumentdepend
requir
appropri
facil
highli
train
technic
staff
perform
complex
diagnost
test
unfortun
none
avail
resourcelimit
area
dengu
diagnost
greatli
benefit
dengu
poc
test
meet
assur
criteria
afford
sensit
specif
rapid
userfriendli
deliv
need
note
laboratori
diagnosi
dengu
achiev
singl
serum
specimen
obtain
febril
phase
ill
test
denv
nucleic
acid
nonstructur
protein
antidenv
igm
current
poc
rdt
detect
antidenv
igm
igg
well
antigen
potenti
chang
current
situat
resourcelimit
area
improv
dengu
clinic
manag
denv
viremia
occur
day
follow
onset
fever
antidenv
igm
begin
appear
around
day
fever
onset
detect
denv
nucleic
acid
rtpcr
sensit
specif
mean
confirm
acut
infect
may
necessarili
reflect
infecti
viru
detect
viral
rna
may
persist
biolog
fluid
infecti
viru
clear
immunoassay
detect
denv
antigen
also
provid
accept
level
sensit
specif
diagnost
approach
instrumentdepend
requir
appropri
facil
perform
complex
diagnost
test
recent
found
apoprotein
h
apo
h
effici
use
detect
bacteria
virus
blood
sampl
describ
dr
francisco
vea
french
institut
dvelop
ird
montpelli
franc
bead
coat
apo
h
readili
captur
virus
glycoproteinrich
envelop
influenza
viru
ebola
viru
denv
arbovirus
even
hcv
bead
easi
use
process
fast
show
high
sensit
one
readili
detect
pfu
viru
ml
whole
blood
dr
rome
buathong
bureau
epidemiolog
dept
diseas
contrtol
thailand
ministri
public
health
remind
audienc
brazilian
outbreak
zikv
littl
known
arboviru
present
mild
denguelik
ill
without
major
complic
initi
spread
subsaharan
africa
asia
without
detect
thu
although
viru
present
thailand
detect
may
canadian
travel
return
thailand
diagnos
diseas
zikv
surveil
program
launch
countri
januari
decemb
reveal
yearli
peak
zikv
infect
raini
season
occur
week
peak
dengu
diseas
total
confirm
case
zikv
infect
record
thailand
two
year
period
age
group
affect
follow
year
group
total
case
zikv
infect
record
pregnant
women
lead
miscarriag
birth
abnorm
includ
case
microcephali
aed
mosquito
countri
found
zikv
posit
rout
transmiss
includ
blood
transfus
sexual
intercours
zikv
rna
could
readili
detect
plasma
saliva
urin
infect
patient
sexual
transmiss
zikv
document
occur
three
week
onset
ill
male
partner
shed
viral
rna
semen
well
document
semen
sampl
pcr
posit
could
shown
contain
infecti
viru
cell
cultur
dr
niko
vasilaki
univers
texa
medic
branch
review
explos
emerg
zikv
south
pacif
south
america
focu
brazil
major
clinic
outcom
pregnant
women
common
alarm
number
zikv
associ
microcephali
gestat
neonat
complic
brought
viru
spotlight
increas
report
syndrom
gb
neurolog
manifest
also
associ
zikv
infect
first
associ
zikv
infect
microcephali
report
recif
brazil
three
women
infect
zikv
pregnanc
deliv
babi
microcephali
retrospect
discov
neurolog
diseas
includ
microcephali
babi
born
zikvinfect
mother
observ
french
polynesia
earli
report
dr
patricia
brasil
oswaldo
cruz
foundat
rio
janeiro
prospect
cohort
studi
zikv
infect
pregnant
women
infant
initi
rio
de
janeiro
earli
zikv
recov
amniot
fluid
placenta
pregnant
women
also
cerebr
spinal
fluid
babi
microcephali
observ
newborn
structur
birth
defect
hyperton
cardiac
defect
ophtalm
abnorm
elbow
abnorm
seizur
observ
newborn
followup
brazilian
babi
born
mother
infect
zikv
pregnanc
show
abnorm
hear
manifest
show
sign
abnorm
behavior
month
age
babi
display
normal
neurodevelop
dr
mauricio
lacerda
nogueira
faculti
medicin
sao
jose
rio
preto
brazil
talk
interplay
variou
flavivirus
given
brazil
hyperendem
arbovirus
concern
previou
heterotyp
flaviviru
eg
dengu
exposur
could
exacerb
zika
diseas
pathogen
denv
antibodi
ab
bind
zikv
could
drive
greater
zikv
replic
antibodydepend
enhanc
ade
phenomenom
initi
describ
denv
also
found
exist
rabi
viru
coxsackieviru
coronavirus
even
hiv
answer
question
cohort
healthi
volunt
vila
toninho
brazil
follow
look
evid
possibl
ade
phenomenom
spite
fact
cohort
denv
ab
start
studi
signific
clinic
differ
could
observ
zikv
infect
denv
ab
posit
denv
ab
neg
person
thu
epidemiolog
evid
brazil
support
hypothesi
previou
exposur
denv
infect
could
enhanc
zikv
pathogen
contrast
report
ab
might
protect
zikv
infect
similarli
presenc
yfv
ab
recent
associ
better
prognosi
zikv
infect
pregnant
women
hypothes
enhanc
infect
zikv
aed
mosquito
confirm
interestingli
mutat
gene
chikv
recent
describ
associ
enhanc
infect
viru
aed
albopictu
mosquito
discuss
dr
niko
vasilaki
convinc
explan
sudden
aggress
zikv
lie
discoveri
yuan
et
al
mutat
prm
gene
brazilian
strain
zikv
could
strongli
contribut
gener
fetal
microcephali
mutat
also
found
zikv
strain
french
polynesia
numer
case
microcephali
record
viru
strain
africa
microcephali
never
observ
dr
marc
lecuit
pasteur
institut
pari
address
question
cellular
molecular
mechan
microcephali
remind
audienc
contrast
chikv
cross
placent
barrier
zikv
readili
penetr
infect
placent
cell
inocul
zikv
brain
mous
embryo
trigger
endoplasm
reticulum
stress
perturb
physiolog
unfold
protein
respons
upr
within
apic
cortic
progenitor
cell
control
neurogenesi
sustain
endoplasm
reticulum
stress
lead
apoptosi
thu
like
pregnant
women
zikv
cross
placent
barrier
get
brain
foetu
cross
bloodbrain
barrier
target
apic
cortic
progenitor
cell
lead
blockad
upr
arrest
neurogenesi
obviou
consequ
microcephali
microcephali
observ
africa
appear
specif
properti
brasilian
zikv
strain
like
relat
prm
mutat
identifi
yuan
et
al
dr
michael
gaunt
london
school
hygien
tropic
medicin
report
seri
experi
done
zikv
denv
identifi
potenti
genet
determin
ade
amino
acid
long
motif
denv
glycoprotein
identifi
might
associ
ade
dr
ann
wildersmith
london
school
hygien
tropic
medicin
review
eu
research
program
zikv
zikaplan
overse
institut
global
partner
plan
set
sustain
latin
american
research
prepared
network
emerg
diseas
longitudin
cohort
studi
subject
age
follow
three
year
differ
locat
brazil
refin
full
spectrum
risk
factor
congenit
zika
syndrom
includ
neurodevelop
mileston
mental
retard
etc
first
year
life
also
address
whether
neurolog
problem
associ
zikv
infect
meningoenceph
acut
zika
myeliti
direct
consequ
zikv
infect
mediat
immun
respons
novel
zikv
diagnost
test
also
develop
dr
loui
lambrecht
pasteur
institut
pari
remind
audienc
aed
aegypti
distribut
throughout
tropic
subtrop
world
contin
serv
major
vector
transmit
urban
arbovirus
includ
denv
zikv
yfv
chikv
etc
wherea
femal
mosquito
take
one
blood
meal
day
aed
aegypti
femal
need
multipl
blood
feed
everi
day
make
effici
transmit
epidem
diseas
comparison
aed
aegypti
ae
albopictu
also
show
although
ae
albopictu
often
suscept
infect
denv
ae
aegypti
appear
significantli
less
effici
transmit
viru
addit
factor
mosquito
genotyp
geograph
locat
strain
arboviru
influenc
transmiss
dynam
diseas
exampl
zikv
infect
ae
aegypti
mosquito
seem
influenc
sequenc
protein
viru
report
dr
scott
ritchi
jame
cook
univers
cairn
australia
use
wolbachia
infect
aed
mosquito
great
potenti
control
spread
arbovirus
transmit
wolbachiainfect
male
aed
mosquito
becom
steril
steril
male
repeatedli
introduc
given
area
resid
aed
popul
suppress
altern
wolbachiainfect
male
femal
mosquito
introduc
togeth
lead
progress
replac
resid
aed
popul
could
show
much
reduc
capac
transmit
denv
zikv
chikv
yfv
possibl
virus
use
wolbachia
recommend
world
mosquito
program
elimin
dengu
trial
australia
demonstr
shortli
releas
wolbachiainfect
aed
mosquito
mosquito
popul
site
becam
wolbachiainfect
transmiss
denv
stop
similar
trial
conduct
viet
nam
indonesia
brazil
fear
wolbachia
infect
ae
aegypti
would
lead
replac
ae
albopictu
seem
unwarr
far
requir
studi
dr
joao
bosco
siqueira
report
brazil
suffer
shortag
yellow
fever
vaccin
fortun
usual
dose
brazilian
vaccin
contain
pfu
attenu
yfv
strain
pfu
suffici
protect
dose
therefor
possibl
use
fraction
dose
vaccin
evid
protect
rel
differ
report
advers
event
face
spread
yellow
fever
throughout
countri
brazilian
govern
updat
vaccin
polici
recommend
entir
popul
vaccin
part
effort
chang
schedul
children
implement
singl
dose
year
age
dose
schedul
first
dose
administ
month
second
dose
year
effort
complic
inadequ
vaccin
suppli
also
fals
rumor
vaccin
would
protect
fake
news
unfortun
power
result
vaccin
refus
rise
popul
review
dr
inkyu
yoon
intern
vaccin
institut
south
korea
dr
christoph
nelson
sanofipasteur
lyon
franc
dr
ann
wildersmith
major
advanc
dengu
research
result
develop
new
vaccin
show
promis
use
dengu
prevent
sanofi
pasteur
recent
licens
cydtdv
dengvaxia
sanofi
pasteur
lyon
franc
six
dengu
vaccin
candid
variou
phase
clinic
trial
cydtdv
tetraval
live
attenu
chimer
vaccin
consist
yfv
genom
premembran
prem
envelop
e
gene
four
antigen
distinct
denv
serotyp
vaccin
undergon
largescal
phase
clinic
trial
asia
latin
america
demonstr
increas
efficaci
age
higher
efficaci
baselin
seroposit
efficaci
highest
prevent
sever
dengu
hospit
moder
overal
dengu
also
vari
serotyp
higher
infect
lower
notabl
third
year
asian
phase
trial
increas
risk
dengu
hospit
seen
children
age
year
efficaci
vaccin
less
year
old
year
old
vaccin
licens
age
indic
year
year
age
countri
cydtdv
vaccin
licens
countri
introduc
public
immun
program
endem
area
philippin
brazil
vaccin
show
high
efficaci
good
safeti
seroposit
person
year
age
group
risk
sever
dengu
observ
individu
naiv
denv
infect
time
vaccin
hypothes
cydtdv
mimic
primari
infect
among
individu
prior
dengu
infect
previous
dengueunexpos
seroneg
secondarylik
infect
among
prior
dengu
infect
previous
dengueexpos
seroposit
retrospect
casecohort
studi
undertakern
analyz
vaccin
safeti
among
dengu
seroposit
seroneg
trial
particip
work
use
result
month
followup
obtain
use
igg
elisa
develop
purpos
data
confirm
substanti
benefit
cydtdv
vaccin
dengu
seroposit
age
year
older
reduc
symptomat
dengu
hospit
dengu
sever
dengu
howev
individu
age
without
evid
prior
dengu
infect
vaccin
elicit
increas
risk
sever
dengu
announc
sanofi
pasteur
novemb
vaccin
therefor
administ
dengu
seroposit
person
obvious
impli
need
prevaccin
screen
strategi
sage
dengu
work
group
review
data
april
sage
committe
recommend
vaccin
evid
past
dengu
infect
seroposit
medic
document
past
dengu
infect
result
implic
dengu
vaccin
candid
clinic
develop
immun
program
polici
program
implement
two
dengu
vaccin
candid
current
phase
clinic
trial
tdv
develop
us
cdc
manufactur
takeda
develop
us
nih
tdv
tetraval
live
attenu
chimer
vaccin
use
attenu
backbon
prem
e
gene
three
denv
serotyp
tdv
vaccin
undergo
phase
trial
brazil
columbia
nicaragua
panama
sri
lanka
thailand
preliminari
phase
data
show
vaccin
safe
good
efficaci
result
uncertain
small
number
case
serotyp
tetraval
live
attenu
vaccin
includ
three
denv
serotyp
undergon
attenu
direct
mutagenesi
basepair
delet
candid
consist
chimera
butantan
institut
brazil
sponsor
butantandv
receiv
regulatori
approv
decemb
begin
phase
trial
brasil
three
denv
vaccin
less
advanc
develop
inactiv
vaccin
dna
vaccin
subunit
e
glycoprotein
vaccin
difficulti
develop
effect
safe
dengu
vaccin
multipl
seen
cydtdv
experi
mani
issu
still
remain
includ
vaccin
elicit
equal
protect
four
denv
serotyp
extrem
difficult
achiev
view
competit
strain
andor
ade
strain
question
rais
whether
realli
must
develop
tetraval
vaccin
whether
antibodi
associ
protect
risk
ade
seem
depend
titer
homotypi
versu
heterotypi
etc
understood
control
sever
diseas
especi
postvaccin
advers
event
vari
age
feasibl
cost
necessari
prevaccin
screen
nevertheless
substanti
public
health
benefit
even
moder
effect
dengu
vaccin
continu
drive
effort
develop
dengu
vaccin
hope
safeti
concern
may
adequ
address
larg
number
zika
vaccin
candid
develop
enter
clinic
trial
includ
mrna
vaccin
dna
vaccin
encod
zikv
prm
e
gene
present
enter
phase
iib
trial
usa
brazil
sever
countri
latin
america
puerto
rico
mexico
panama
peru
columbia
purifi
inactiv
vaccin
adjuv
alum
shown
immunogen
two
dose
im
rout
phase
clinic
trial
chimer
measl
viru
vaccin
express
prm
e
gene
zikv
outlin
dr
anna
durbin
john
hopkin
bloomberg
school
public
health
mani
hurdl
still
remain
licensur
safe
effect
zikv
vaccin
occur
transmiss
zikv
declin
much
difficult
perform
phase
efficaci
studi
addit
clinic
trial
efficaci
endpoint
zikv
vaccin
well
establish
one
wonder
vaccin
fulli
prevent
infect
order
prevent
microcephali
high
bar
vaccin
inde
dr
georg
thiri
sa
senergu
franc
report
creation
coalit
epidem
preparad
innov
cepi
launch
januari
oslo
london
washington
aim
prevent
futur
epidem
develop
new
vaccin
three
major
target
select
manufactur
test
candid
vaccin
merscov
lassa
fever
viru
nipah
viru
cepi
respons
vaccin
develop
preclin
phase
trial
sever
vaccin
follow
lassavsv
vaccin
develop
iavi
lassadna
vaccin
lassameasl
mv
vaccin
develop
themi
merscovmv
vaccin
also
develop
themi
nipah
glycoprotein
subunit
vaccin
adjuv
phase
studi
taken
place
phase
trial
expect
follow
arbovirus
news
top
social
polit
public
health
agenda
arboviru
epidem
increasingli
threaten
global
nation
local
polit
econom
secur
creat
global
public
health
emerg
increas
risk
epidem
arbovir
diseas
rural
area
also
increas
risk
urban
epidem
dengu
epidem
recent
seen
amplitud
increas
dramat
fold
report
case
denv
infect
brazil
preced
year
lead
death
period
dengueinfect
person
hospit
bangladesh
death
occur
death
dengu
report
philippin
estim
million
dengu
infect
occur
annual
develop
vaccin
vector
control
tool
prevent
arboviru
diseas
activ
pursu
possibl
develop
trival
vaccin
zikv
chikv
wnv
even
entertain
mani
hurdl
howev
remain
licensur
safe
effect
zikv
vaccin
occur
outlin
similarli
difficulti
develop
effect
safe
denv
vaccin
multipl
mani
question
still
aris
cost
implement
prevaccin
screen
vaccin
place
denv
seroposit
year
age
turn
low
singapor
exampl
dramat
emerg
spread
epidem
arbovir
diseas
made
necessari
reassess
surveil
strategi
atrisk
countri
enhanc
passiv
diseas
surveil
system
base
welldefin
case
definit
support
serolog
virolog
laboratori
test
activ
laboratori
syndrom
surveil
system
develop
past
influenza
poliomyel
badli
need
hope
system
set
rapidli
also
need
effect
mosquito
control
tool
use
conjunct
vaccin
time
access
clinic
seric
appropri
care
use
integr
approach
prevent
control
abl
success
revers
trend
emerg
epidem
arbovir
diseas
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
